Omeros Corp. started a registered underwritten public offering of 3 million common shares.

The company also granted the underwriter an option to buy up to an additional 450,000 shares.

Omeros plans to use the net proceeds for general corporate purposes, including expenses related to funding research and development for its OMS721 programs and clinical trials, preclinical studies, manufacturing and other costs associated with advancing its product candidates toward submissions.

The proceeds may also be used by Omeros for working capital, the repayment of debt obligations, acquisitions or investments in businesses, products or technologies that are complementary to its own and other capital expenditures.

Cantor Fitzgerald & Co. is acting as the book runner for the offering.